These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25658233)

  • 41. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.
    Elishmereni M; Kheifetz Y; Shukrun I; Bevan GH; Nandy D; McKenzie KM; Kohli M; Agur Z
    Prostate; 2016 Jan; 76(1):48-57. PubMed ID: 26419619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.
    Maroto P; Solsona E; Gallardo E; Mellado B; Morote J; Arranz JÁ; Gómez-Veiga F; Unda M; Climent MÁ; Alcaraz A
    Crit Rev Oncol Hematol; 2016 Apr; 100():127-36. PubMed ID: 26363809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate cancer: Charting a course in metastatic castration-sensitive prostate cancer.
    Madan RA; Dahut WL
    Nat Rev Urol; 2015 Jul; 12(7):368-9. PubMed ID: 26077994
    [No Abstract]   [Full Text] [Related]  

  • 44. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 45. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
    Hakariya T; Sakai H
    Nihon Rinsho; 2016 Jan; 74(1):137-42. PubMed ID: 26793894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
    Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
    Sasaki T; Onishi T; Hoshina A
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
    Kamoto T
    Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer.
    Osmulski P; Mahalingam D; Gaczynska ME; Liu J; Huang S; Horning AM; Wang CM; Thompson IM; Huang TH; Chen CL
    Prostate; 2014 Sep; 74(13):1297-307. PubMed ID: 25065737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.
    Heidegger I; Heidenreich A; Pfister D
    Target Oncol; 2017 Feb; 12(1):37-45. PubMed ID: 27796762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific antigen growth rate constant after first-line cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a monoinstitutional experience.
    Colloca G; Venturino A; Addamo G; Ratti R; Coccorullo Z; Caltabiano G; Viale G; Guarneri D
    Urol Oncol; 2014 Jan; 32(1):42.e1-5. PubMed ID: 24239469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
    Miyake H; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2020 Feb; 40(2):1101-1106. PubMed ID: 32014960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer.
    Ranasinghe L; Cotogno P; Ledet E; Bordlee B; Degeyter K; Nguyen N; Steinberger A; Manogue C; Barata P; Lewis BE; Sartor AO
    Cancer Treat Res Commun; 2019; 20():100151. PubMed ID: 31128516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Utility of Serum CA9 for Prognostication in Prostate Cancer.
    Smith AD; Truong M; Bristow R; Yip P; Milosevic MF; Joshua AM
    Anticancer Res; 2016 Sep; 36(9):4489-92. PubMed ID: 27630286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.